Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ron Mark

Diagnostic Radiology Deer Park, NY Medical Doctor

NPI 1013917301 CMS profile 562724

2103 Deer Park Ave, Deer Park, NY 11729

Open in the dashboard

General payments

$173,327

111 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ron Mark of Deer Park, NY is reported in the CMS Open Payments database as having received $173,327 across 111 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,060 8
2024 General $24,430 26
2023 General $24,967 15
2022 General $25,514 22
2021 General $24,633 12
2020 General $24,280 10
2019 General $25,444 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ron Mark
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Ron Mark were reported at $24,060. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Ron Mark Diagnostic Radiology median Middle half National median
2019 $25,444 $108 $29–$318 $163
2020 $24,280 $65 $21–$252 $114
2021 $24,633 $92 $24–$292 $132
2022 $25,514 $104 $29–$294 $149
2023 $24,967 $110 $29–$337 $160
2024 $24,430 $113 $30–$356 $164
2025 $24,060 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $168,090 36 payments
  2. Merz North America, Inc. $2,734 19 payments
  3. Boston Scientific Corporation $1,897 26 payments
  4. Tactile Systems Technology Inc $540 27 payments
  5. Biocompatibles, Inc. $37 2 payments
  6. Allergan Inc. $30 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $96,000 20 payments
  2. Education $72,000 15 payments
  3. Food and Beverage $4,202 72 payments
  4. Travel and Lodging $1,125 4 payments
Products named General payments · program years 2019–2025
  1. VenaCure 1470 Pro Et $96,000 20 payments
  2. EVLT $48,000 10 payments
  3. VenaCure 1470 Pro Id $24,000 5 payments
  4. Xeomin $2,734 19 payments
  5. ANGIOJET $1,381 11 payments
  6. Flexitouch Plus $540 27 payments
  7. Entre Plus $480 24 payments
  8. WALLSTENT $100 1 payment
  9. Auryon Laser System 100-120 Vac $90 1 payment
  10. GENERAL ATHERECTOMY $77 1 payment
  11. Other $465 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

152

Median for Interventional Radiology: 38

Drug cost

$716

Median for Interventional Radiology: $333

Branded share of claims

0%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ibuprofen Generic 82 $259
Triamcinolone Acetonide Generic 17 $250
Celecoxib Generic 17 $131
Naproxen Generic 22 $68
Alprazolam Generic 14 $9

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 138 billing codes

Paid by Medicare

$247,639

Medicare's payments for the services billed

Medicare patients

2,373

Average age 75

Services billed

4,046

1,515 women, 858 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 54%
Chronic kidney disease 41%
Ischemic heart disease 36%
Depression 31%
Heart failure 28%
Osteoporosis 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

111 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record